Sector | Healthcare |
Industry | - |
Day Range | 245.81 | 249.10 |
52-Wk Range | - | - |
Last Close | 248.95 |
Mkt Cap (m) | 143,346.03 |
Dividend yield | 2.64 |
ISIN | US0311621009 |
Volume | 1,368,801.00 |
Exchange Venue | NAS |
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
Price/Earning | 20.22 |
Price/Book | 15.24 |
Price/Sales | 5.78 |
P/CF | 13.99 |
Rev Growth (3 year avg) | 3.62 |
EPS Growth (3 year avg) | 0.66 |
Operating Margin % | 35.95 |
Net Margin % | 28.57 |
Return on Equity | 76.13 |
Debt/Equity | 3.51 |
en 06/05/2020 |
en 31/12/2020 |
Please refer to the below issuer website for further documents.
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 21,662.00 | 22,991.00 | 22,849.00 | 23,747.00 | 23,362.00 | 25,424.00 |
Operating Income (m) | 8,470.00 | 9,794.00 | 9,973.00 | 10,263.00 | 9,674.00 | 9,139.00 |
Net Income (m) | 6,939.00 | 7,722.00 | 1,979.00 | 8,394.00 | 7,842.00 | 7,264.00 |
Basic EPS | 9.15 | 10.32 | 2.71 | 12.70 | 12.96 | 12.40 |
Avg. Diluted Shares Outstanding (m) | 766.00 | 754.00 | 735.00 | 665.00 | 609.00 | 590.00 |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 38,518.00 | 46,010.00 | 49,476.00 | 37,618.00 | 18,440.00 | 21,144.00 |
Non Current Assets (m) | 33,058.00 | 31,616.00 | 30,478.00 | 28,798.00 | 41,267.00 | 41,804.00 |
Total Assets (m) | 71,576.00 | 77,626.00 | 79,954.00 | 66,416.00 | 59,707.00 | 62,948.00 |
Current Liabilities (m) | 8,667.00 | 11,204.00 | 9,020.00 | 13,488.00 | 12,835.00 | 11,653.00 |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | 28,083.00 | 29,875.00 | 25,241.00 | 12,500.00 | 9,673.00 | 9,409.00 |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | 9,077.00 | 10,354.00 | 11,177.00 | 11,296.00 | 9,150.00 | 10,497.00 |
Capital Expenditure (m) | -649.00 | -837.00 | -664.00 | -738.00 | -618.00 | -608.00 |